Pharmaceutical companies are under escalating pressure to significantly increase the number of drugs that reach the market within a shorter timeframe, but lack the infrastructure to do so. More than ever, companies need to partner with outside firms to compress…
At the dawn of bioprocess development, biopharmaceutical manufacturing, upstream and downstream primary processing were worlds apart. This is because, in the pre-biotech days of industrial bioprocessing, the professionals in upstream, usually biologists, microbiologists…
Understanding the volume and complexity of data created throughout the scientific process is key. Biopharmaceutical companies generate a vast amount of high-value process data that is typically stored in paper records, databases, electronic files and in the heads of key…
